

Amendments to the Claims:

The listing of claims set forth below is to replace all prior versions, and listings, of claims in the present application.

Listing of Claims:

Claim 1 (currently amended): A kit of parts comprising two or more protein kinase substrate polypeptides, each said substrate polypeptide comprising a specificity conferring portion, wherein the specificity conferring portion is different for each said substrate polypeptide, and a phosphorylatable portion, wherein the phosphorylatable portion of each said substrate polypeptide is SEQ ID NO:6 having ~~up to five~~ no ~~resides (other than serine) conservatively~~ substituted and capable of being bound in a phosphorylation state-sensitive manner by a specific binding partner that is not an antibody specific for phosphotyrosine, phosphoserine or phosphothreonine.

Claim 2 (canceled).

Claim 3 (previously presented): A kit of parts as defined in claim 1 wherein the phosphorylatable portion of at least one said polypeptide is phosphorylated.

Claim 4 (previously presented): The kit of claim 1 wherein each said polypeptide is of less than 40, 30, 20, 19, 18, 17, 16, 15, or 14 amino acids in length.

Claim 5 (original): The kit of claim 4 wherein said polypeptide is 13, 12, 11, 10 or 9 amino acids in length.

Claim 6 (previously presented): The kit of claim 5 wherein the protein kinase substrate polypeptide is a substrate for a serine/threonine protein kinase.

Claim 7 (canceled).

Claim 8 (previously presented): The kit of claim 1 further comprising the specific binding partner.

Claim 9 (previously presented): The kit of claim 8 wherein the specific binding partner is an antibody.

Claim 10 (previously presented): An antibody specific for the epitope formed by the amino acid sequence of SEQ ID NO:6.

Claim 11 (previously presented): An antibody specific for the epitope formed by the amino acid sequence of LpSFAEPG (SEQ ID NO:7).

Claim 12 (currently amended): A polypeptide of less than 40, 30, 20, 19, 18, 17, 16, 15, or 14 amino acids in length wherein the polypeptide is not a fragment of glycogen synthase

- 5 -

kinase 3, and wherein the polypeptide comprises SEQ ID NO: 6 having ~~up to five~~ no ~~resides (other than serine)~~ conservatively substituted and further comprising a specificity conferring portion comprising an amino acid sequence corresponding to a consensus sequence for a protein kinase, wherein the sequence corresponding to the consensus sequence is positioned relative to SEQ ID NO: 6 such that the protein kinase is capable of phosphorylating the polypeptide at the serine residue of SEQ ID NO:6.

Claim 13 (original): The polypeptide of claim 12 wherein the polypeptide is 13, 12, 11, 10, or 9 amino acids in length.

Claim 14 (previously presented): The polypeptide of claim 12 wherein the amino acid sequence corresponding to the consensus sequence extends to the N-terminus of SEQ ID NO: 6.

Claim 15 (previously presented): The polypeptide of claim 12 wherein the consensus sequence is SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:2, or SEQ ID NO:5.

Claim 16 (previously presented): A polypeptide according to claim 12 in which the serine residue of SEQ ID NO:6 is replaced by phosphoserine.

Claim 17 (canceled).

Claim 18 (canceled).

Claim 19 (withdrawn): A method for screening for protein kinases in a sample which may contain protein kinases comprising exposing a polypeptide as defined in claim 12 to the sample and determining whether and optionally to what extent said polypeptide is phosphorylated.

Claim 20 (withdrawn): A method for assaying the activity of a protein kinase, comprising the steps of exposing the protein kinase to a polypeptide according to claim 12 and determining whether and optionally to what extent said polypeptide is phosphorylated.

Claim 21 (withdrawn): A method of assessing the activity of a first protein kinase and a second protein kinase, comprising the steps of exposing the first protein kinase to a first polypeptide of a kit according to claim 1, and exposing the second protein kinase to a second polypeptide of a kit according to claim 1; and determining whether and optionally to what extent said polypeptide is phosphorylated.

Claim 22 (withdrawn - currently amended): A method for assessing the activity of a protein kinase, comprising the steps of exposing the protein kinase to a first (unphosphorylated) peptide of a kit of ~~claim 2~~ claim 1, and determining whether and optionally to what extent said polypeptide is phosphorylated.

Claim 23 (withdrawn): A method for characterising the substrate specificity of a protein kinase, comprising the

steps of exposing the protein kinase to a first polypeptide of a kit of claim 1, and exposing the protein kinase to a second polypeptide of a kit of claim 1; and determining whether and optionally to what extent said polypeptides are phosphorylated.

Claim 24 (previously presented): The kit of parts according to claim 1 wherein said specific binding partner is an antibody.

Claim 25 (previously presented): The kit of parts according to claim 1 wherein the specific binding partner for the phosphorylatable portion of each said substrate polypeptide is the same.